rofecoxib has been researched along with Kidney Failure, Chronic in 1 studies
Kidney Failure, Chronic: The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Vitamin D deficiency is common in chronic kidney disease (CKD)." | 1.38 | Antiproteinuric treatment reduces urinary loss of vitamin D-binding protein but does not affect vitamin D status in patients with chronic kidney disease. ( de Borst, MH; de Cuba, MM; Doorenbos, CR; Gans, RO; Kema, IP; Navis, G; van den Born, J; Vogt, L, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Doorenbos, CR | 1 |
| de Cuba, MM | 1 |
| Vogt, L | 1 |
| Kema, IP | 1 |
| van den Born, J | 1 |
| Gans, RO | 1 |
| Navis, G | 1 |
| de Borst, MH | 1 |
1 other study available for rofecoxib and Kidney Failure, Chronic
| Article | Year |
|---|---|
Antiproteinuric treatment reduces urinary loss of vitamin D-binding protein but does not affect vitamin D status in patients with chronic kidney disease.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Cyclooxygenase Inhibitors; Drug Therapy, Comb | 2012 |